Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

- PMLiVE

UK confirms first cases of coronavirus as global concerns mount

Pharma industry steps up its efforts to develop therapeutics for infection

- PMLiVE

Lilly posts higher-than-expected profit as new drugs lift outlook

Sales boosted by growth of Trulicity and Taltz

- PMLiVE

Astellas files new application for expanded use of roxadustat in Japan

Aims for use in anaemia associated with CKD in non-dialysis patients

- PMLiVE

It’s Brexit day – now comes the really hard stuff

Months of trade negotiations between UK and EU lie ahead

- PMLiVE

Caroline Benson and Colin Williams to Chair the PM Society from February 2020

For the first time both industry and agencies will be equally represented as the PM Society appoints a joint chair.

Cuttsy + Cuttsy

- PMLiVE

Will biosimilars ever catch on in the US?

Why biosimilars are viewed in the US as ‘me too’ drugs rather than as just-as-good alternatives to branded products

- PMLiVE

Lucid Learning and Development

Julianne Tate, Head of Learning and Development at Lucid Group, discusses the new programmes and tools that she has been busy developing and rolling out throughout the Group — Elevating...

Lucid Group Communications Limited

- PMLiVE

Roche posts minor sales miss in Q4 as biosimilar pressure grows

Swiss pharma still managed an 8% increase in pharma sales

The role of medical affairs in positive and appropriate engagement with patient advocacy groups

Written by Gavin Jones, Dr Alexandra Safronova & Professor Peter Rutherford, OPEN Health

OPEN Health

- PMLiVE

J&J begins search for a coronavirus vaccine as confirmed cases rise

Death toll has now reached 170, with 7,711 confirmed cases in China

Sanofi reception

Sanofi’s rare disease drug olipudase alfa scores in late-stage study

Met crucial endpoints across two clinical studies

- PMLiVE

J&J gets EMA nod for wider use of Erleada in prostate cancer

Maintains a regulatory lead over rival Xtandi

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links